Analyst Ratings for Prelude Therapeutics (PRLD)
PRLD Rating Summary
PRLD Price Target Summary
- Highest: $12.00 (JPMorgan)
- Lowest: $6.00 (Citizens)
- Average: $9.17
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$9.17 (+181.2%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
Avg. $ Target:
$9.17 (+181.2%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/18/2026 | Evercore ISI | Gavin Clark-Gartner | New Coverage | Outperform (N/A) |
10.00 (N/A) |
4.57 (3.26) |
-28.67% | Details |
| 9/17/2026 | JPMorgan | Joyce Zhou | New Coverage | Overweight (N/A) |
12.00 (N/A) |
4.52 (3.26) |
-27.88% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
